Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A disease mutation reveals a role for NaV1.9 in acute itch
Juan Salvatierra, … , Xinzhong Dong, Frank Bosmans
Juan Salvatierra, … , Xinzhong Dong, Frank Bosmans
Published November 5, 2018
Citation Information: J Clin Invest. 2018;128(12):5434-5447. https://doi.org/10.1172/JCI122481.
View: Text | PDF
Research Article Neuroscience

A disease mutation reveals a role for NaV1.9 in acute itch

  • Text
  • PDF
Abstract

Itch (pruritis) and pain represent two distinct sensory modalities; yet both have evolved to alert us to potentially harmful external stimuli. Compared with pain, our understanding of itch is still nascent. Here, we report a new clinical case of debilitating itch and altered pain perception resulting from the heterozygous de novo p.L811P gain-of-function mutation in NaV1.9, a voltage-gated sodium (NaV) channel subtype that relays sensory information from the periphery to the spine. To investigate the role of NaV1.9 in itch, we developed a mouse line in which the channel is N-terminally tagged with a fluorescent protein, thereby enabling the reliable identification and biophysical characterization of NaV1.9-expressing neurons. We also assessed NaV1.9 involvement in itch by using a newly created NaV1.9–/– and NaV1.9L799P/WT mouse model. We found that NaV1.9 is expressed in a subset of nonmyelinated, nonpeptidergic small-diameter dorsal root ganglia (DRGs). In WT DRGs, but not those of NaV1.9–/– mice, pruritogens altered action potential parameters and NaV channel gating properties. Additionally, NaV1.9–/– mice exhibited a strong reduction in acute scratching behavior in response to pruritogens, whereas NaV1.9L799P/WT mice displayed increased spontaneous scratching. Altogether, our data suggest an important contribution of NaV1.9 to itch signaling.

Authors

Juan Salvatierra, Marcelo Diaz-Bustamante, James Meixiong, Elaine Tierney, Xinzhong Dong, Frank Bosmans

×

Figure 5

APs are influenced by NaV1.9 and CQ.

Options: View larger image (or click on image) Download as PowerPoint
APs are influenced by NaV1.9 and CQ.
(A) Representative APs for WT (blue...
(A) Representative APs for WT (blue), NaV1.9–/– (green), WT in the presence of CQ (100 μM, red), and NaV1.9–/– mice in the presence of CQ (100 μM, purple). Dotted lines represent the resting membrane potential (RMP) for WT and NaV1.9–/–: –40.0 ± 1.3 mV and –31.5 ± 2.7 mV, respectively (n = 13 for WT and n = 12 for NaV1.9–/–; **P = 0.009). (B) Quantification of AP parameters in WT and NaV1.9–/– DRGs. Amplitude of AP (WT n = 16 and NaV1.9–/– n = 20, P = 0.44) and threshold to elicit an AP were not affected (WT n = 20 and NaV1.9–/– n = 20, P = 0.67). NaV1.9–/– APs had a slower time to peak (T to peak; WT n = 17 and NaV1.9–/– n = 20, P = 0.016) and a faster time to minimum (T to min; WT n = 21 and NaV1.9–/– n = 18, P = 0.004). (C) CQ treatment affects the AP amplitude and threshold but not kinetics. Amplitude of AP (WT n = 16 and with CQ n = 16, P = 0.002) and threshold to elicit an AP (WT n = 20 and with CQ n = 16, P = 0.033) were significantly lower. T to peak (WT n = 17 and with CQ n = 17, P = 0.063) and T to min (WT n = 21 and with CQ n = 18, P = 0.732) were not significantly different. (D) These effects do not occur in NaV1.9–/– DRGs: AP (NaV1.9–/– n = 20 and with CQ n = 12, P = 0.5), the threshold to elicit an AP (NaV1.9–/– n = 20 and with CQ n = 12, P = 0.855), T to peak (NaV1.9–/– n = 20 and with CQ n = 12, P = 0.219), and T to min (NaV1.9–/– n = 18 and with CQ n = 16, P = 0.157) were not statistically significant. *P < 0.05, **P < 0.01, by 2-tailed, unpaired Student’s t test was used for RMP, and Mann-Whitney was used for all other data comparisons, which are represented as mean ± SEM. See Table 1 for values.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts